

Antonio Rossi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8758084/antonio-rossi-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260
papers

7,227
citations

41
h-index

74
g-index

269
ext. papers

8,250
ext. citations

5
avg, IF

5.64
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 260 | Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 362-72 | 9.7 | 673 |
| 259 | Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6865-72 | 2.2 | 394 |
| 258 | Non-small-cell lung cancer. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15009 | 51.1 | 352 |
| 257 | Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1692-8 | 2.2 | 292 |
| 256 | Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 745-52 | 10.2 | 217 |
| 255 | First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3002-11 | 2.2 | 193 |
| 254 | Testing for ROS1 in non-small cell lung cancer: a review with recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 469, 489-503 | 5.1 | 146 |
| 253 | Lung cancer in the elderly. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1898-907 | 2.2 | 116 |
| 252 | The potential role of mTOR inhibitors in non-small cell lung cancer. <i>Oncologist</i> , 2008 , 13, 139-47 | 5.7 | 98 |
| 251 | Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. <i>Oncologist</i> , 2007 , 12, 191-200 | 5.7 | 92 |
| 250 | Erlotinib in non-small cell lung cancer treatment: current status and future development. <i>Oncologist</i> , 2007 , 12, 840-9 | 5.7 | 90 |
| 249 | Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 653-60 | 3.5 | 83 |
| 248 | Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology</i> , 2007 , 8, 500-12 | 21.7 | 80 |
| 247 | Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. <i>Oncogene</i> , 2003 , 22, 6629-38 | 9.2 | 80 |
| 246 | Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 464, 61-8 | 5.1 | 77 |
| 245 | Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2013 , 14, 469-75 | 4.6 | 75 |
| 244 | Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. <i>European Journal of Human Genetics</i> , 2014 , 22, 32-9 | 5.3 | 74 |

| | | | |
|-----|---|------|----|
| 243 | Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option?. <i>Oncology</i> , 2009 , 77 Suppl 1, 113-21 | 3.6 | 73 |
| 242 | Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2014 , 15, 1254-62 | 21.7 | 71 |
| 241 | EGFR mutations in lung cancer: from tissue testing to liquid biopsy. <i>Future Oncology</i> , 2015 , 11, 1611-23 | 3.6 | 70 |
| 240 | Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome. <i>European Respiratory Journal</i> , 2016 , 47, 1829-41 | 13.6 | 70 |
| 239 | Treatment of advanced non small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2011 , 3, 122-33 | 2.6 | 69 |
| 238 | ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. <i>Targeted Oncology</i> , 2013 , 8, 55-67 | 5 | 66 |
| 237 | Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?. <i>European Respiratory Review</i> , 2014 , 23, 308-19 | 9.8 | 65 |
| 236 | Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2003 , 89, 1827-9 | 8.7 | 61 |
| 235 | Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. <i>Oncologist</i> , 2009 , 14, 612-20 | 5.7 | 60 |
| 234 | Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. <i>Current Drug Safety</i> , 2016 , 11, 62-8 | 1.4 | 59 |
| 233 | The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 104, 9-20 | 7 | 57 |
| 232 | Endobronchial metastasis: an epidemiologic and clinicopathologic study of 174 consecutive cases. <i>Lung Cancer</i> , 2014 , 84, 222-8 | 5.9 | 56 |
| 231 | Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. <i>Lung Cancer</i> , 2014 , 86, 291-5 | 5.9 | 51 |
| 230 | Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. <i>Cancer Treatment Reviews</i> , 2013 , 39, 466-72 | 14.4 | 51 |
| 229 | The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. <i>Oncologist</i> , 2007 , 12, 1183-93 | 5.7 | 51 |
| 228 | Prognostic value of circulating tumor cells reduction in patients with extensive small-cell lung cancer. <i>Lung Cancer</i> , 2014 , 85, 314-9 | 5.9 | 50 |
| 227 | Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. <i>Lung Cancer</i> , 2010 , 70, 119-28 | 5.9 | 48 |
| 226 | Characterization of specific immune responses to different <i>Aspergillus</i> antigens during the course of invasive <i>Aspergillosis</i> in hematologic patients. <i>PLoS ONE</i> , 2013 , 8, e74326 | 3.7 | 47 |

| | | | |
|-----|---|------|----|
| 225 | Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. <i>Lung Cancer</i> , 2011 , 72, 378-83 | 5.9 | 46 |
| 224 | Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?. <i>Oncologist</i> , 2009 , 14, 137-47 | 5.7 | 45 |
| 223 | Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1282-1292 | 8.9 | 45 |
| 222 | Treatment of small cell lung cancer in the elderly. <i>Oncologist</i> , 2005 , 10, 399-411 | 5.7 | 44 |
| 221 | Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. <i>Annals of Oncology</i> , 2011 , 22, 1528-1534 | 10.3 | 42 |
| 220 | Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids. <i>European Journal of Cardio-thoracic Surgery</i> , 2014 , 45, 677-86 | 3 | 41 |
| 219 | Pemetrexed in the treatment of advanced non-squamous lung cancer. <i>Lung Cancer</i> , 2009 , 66, 141-9 | 5.9 | 40 |
| 218 | Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e49-51 | 8.9 | 40 |
| 217 | Pathology of Sarcoidosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015 , 49, 36-44 | 12.3 | 39 |
| 216 | The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 68, 29-36 | 7 | 39 |
| 215 | Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. <i>Therapeutic Advances in Medical Oncology</i> , 2015 , 7, 263-73 | 5.4 | 38 |
| 214 | Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol description. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 107-14 | 4.9 | 38 |
| 213 | Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 221-9 | 8.9 | 38 |
| 212 | A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1091-4 | 8.9 | 37 |
| 211 | Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2011 , 43, 286-94 | 3.3 | 36 |
| 210 | Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , 2015 , 17, 391-5 | 8.1 | 35 |
| 209 | Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. <i>Cancer Treatment Reviews</i> , 2013 , 39, 498-506 | 14.4 | 34 |
| 208 | Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 561-70 | 4 | 33 |

| | | | |
|-----|---|-----|----|
| 207 | Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. <i>Oncologist</i> , 2009 , 14, 909-20 | 5.7 | 33 |
| 206 | New targeted therapies and small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2008 , 9, 271-9 | 4.9 | 33 |
| 205 | Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. <i>Translational Lung Cancer Research</i> , 2016 , 5, 301-21 | 4.4 | 33 |
| 204 | Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 1005-17 | 5.1 | 32 |
| 203 | Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , 2018 , 19, 93-104 | 4.9 | 31 |
| 202 | Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 758-61 | 8.9 | 31 |
| 201 | Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal. <i>Lung Cancer</i> , 2015 , 87, 226-31 | 5.9 | 30 |
| 200 | ALK inhibitors and advanced non-small cell lung cancer (review). <i>International Journal of Oncology</i> , 2014 , 45, 499-508 | 4.4 | 30 |
| 199 | Localized pleuropulmonary crystal-storing histiocytosis: 5 cases of a rare histiocytic disorder with variable clinicoradiologic features. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 906-12 | 6.7 | 30 |
| 198 | The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation. <i>Current Medicinal Chemistry</i> , 2012 , 19, 3337-52 | 4.3 | 30 |
| 197 | K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature. <i>Lung Cancer</i> , 2016 , 93, 55-8 | 5.9 | 29 |
| 196 | Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. <i>Oncologist</i> , 2009 , 14, 601-11 | 5.7 | 29 |
| 195 | First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. <i>Journal of Clinical Gastroenterology</i> , 2003 , 36, 228-33 | 3 | 28 |
| 194 | Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016 , 18, 59 | 6.3 | 28 |
| 193 | Mucorales-Specific T Cells in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2016 , 11, e0149108 | 3.7 | 27 |
| 192 | BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016 , 17, 461-465 | 4.9 | 27 |
| 191 | MET and Small-Cell Lung Cancer. <i>Cancers</i> , 2014 , 6, 2100-15 | 6.6 | 26 |
| 190 | Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies: analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas. <i>American Journal of Surgical Pathology</i> , 2014 , 38, 502-9 | 6.7 | 26 |

| | | | |
|-----|---|------|----|
| 189 | Treating advanced non-small cell lung cancer in the elderly. <i>Therapeutic Advances in Medical Oncology</i> , 2010 , 2, 251-60 | 5.4 | 26 |
| 188 | Advances in chemotherapy in advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2997-3007 | 4 | 26 |
| 187 | Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?. <i>Cancer Treatment Reviews</i> , 2013 , 39, 489-97 | 14.4 | 25 |
| 186 | A "live" biopsy in a small-cell lung cancer patient by detection of circulating tumor cells. <i>Lung Cancer</i> , 2009 , 65, 123-5 | 5.9 | 25 |
| 185 | Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?. <i>Lung Cancer</i> , 2009 , 66, 8-14 | 5.9 | 25 |
| 184 | Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2014 , 15, 166-70 | 4.9 | 24 |
| 183 | Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients. <i>Lung Cancer</i> , 2014 , 86, 324-8 | 5.9 | 24 |
| 182 | Biological prognostic and predictive factors in lung cancer. <i>Oncology</i> , 2009 , 77 Suppl 1, 90-6 | 3.6 | 24 |
| 181 | Recent developments of targeted therapies in the treatment of non-small cell lung cancer. <i>Current Drug Discovery Technologies</i> , 2009 , 6, 91-102 | 1.5 | 24 |
| 180 | Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 1963-71 | 5.4 | 24 |
| 179 | The role of antiangiogenetic agents in the treatment of breast cancer. <i>Current Medicinal Chemistry</i> , 2011 , 18, 5022-32 | 4.3 | 23 |
| 178 | Treatment of advanced non-small-cell lung cancer in the elderly. <i>Lung Cancer</i> , 2009 , 66, 282-6 | 5.9 | 23 |
| 177 | Frequent fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. <i>Oncotarget</i> , 2018 , 9, 9661-9671 | 3.3 | 23 |
| 176 | Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. <i>Anticancer Research</i> , 2003 , 23, 1657-64 | 2.3 | 23 |
| 175 | Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. <i>Anticancer Research</i> , 2010 , 30, 1301-10 | 2.3 | 23 |
| 174 | Current and future therapeutic approaches for the treatment of small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 473-486 | 3.5 | 22 |
| 173 | Medical treatment of small cell lung cancer: state of the art and new development. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 2019-31 | 4 | 22 |
| 172 | The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making. <i>Current Medicinal Chemistry</i> , 2010 , 17, 1030-8 | 4.3 | 22 |

| | | | |
|-----|---|------|----|
| 171 | Supportive care in patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2003 , 89, 1013-21 | 8.7 | 22 |
| 170 | Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies. <i>Current Clinical Pharmacology</i> , 2016 , 11, 77-87 | 2.5 | 22 |
| 169 | Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. <i>Lung Cancer</i> , 2011 , 73, 1-10 | 5.9 | 21 |
| 168 | A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. <i>Clinical Lung Cancer</i> , 2007 , 8, 396-8 | 4.9 | 21 |
| 167 | The role of targeted therapy in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 51, 29-44 | 7 | 21 |
| 166 | Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study. <i>Lung Cancer</i> , 2000 , 29, 131-7 | 5.9 | 21 |
| 165 | Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. <i>British Journal of Cancer</i> , 2003 , 89 Suppl 2, S19-23 | 8.7 | 20 |
| 164 | Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 30, 212-4 | 3.5 | 20 |
| 163 | The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. <i>Cancer Treatment Reviews</i> , 2014 , 40, 485-94 | 14.4 | 19 |
| 162 | ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1470-6 | 8.9 | 19 |
| 161 | Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <i>Lung Cancer</i> , 2010 , 67, 86-92 | 5.9 | 19 |
| 160 | New antiangiogenetic agents and non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 60, 76-86 | 7 | 19 |
| 159 | Screening for lung cancer: New horizons?. <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 56, 311-20 | 7 | 19 |
| 158 | Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1540-6 | 8.9 | 18 |
| 157 | A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. <i>Clinical Lung Cancer</i> , 2007 , 8, 568-71 | 4.9 | 18 |
| 156 | Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. <i>Lung Cancer</i> , 2005 , 47, 421-3 | 5.9 | 18 |
| 155 | Classification of different patterns of pulmonary adenocarcinomas. <i>Expert Review of Respiratory Medicine</i> , 2015 , 9, 571-86 | 3.8 | 17 |
| 154 | A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. <i>Clinical Lung Cancer</i> , 2013 , 14, 461-5 | 4.9 | 17 |

| | | | |
|-----|--|------|----|
| 153 | Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1830-1844 | 8.9 | 17 |
| 152 | Ligand-dependent activation of EGFR in follicular dendritic cells sarcoma is sustained by local production of cognate ligands. <i>Clinical Cancer Research</i> , 2013 , 19, 5027-38 | 12.9 | 17 |
| 151 | The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 631-9 | 5.9 | 17 |
| 150 | Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. <i>Lung Cancer</i> , 2002 , 36, 327-32 | 5.9 | 17 |
| 149 | The prognostic role of circulating tumor cells in lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 859-67 | 3.5 | 16 |
| 148 | The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16 Suppl 2, S45-54 | 6.4 | 16 |
| 147 | The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. <i>Current Genomics</i> , 2008 , 9, 252-62 | 2.6 | 16 |
| 146 | Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: current status and future development. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 68, 222-32 | 7 | 16 |
| 145 | Cetuximab in advanced non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 59, 139-49 | 7 | 16 |
| 144 | Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients. <i>Expert Opinion on Drug Safety</i> , 2005 , 4, 1051-67 | 4.1 | 16 |
| 143 | Alectinib for ALK-positive non-small-cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 1005-13 | 3.8 | 15 |
| 142 | New molecular targets in the treatment of NSCLC. <i>Current Pharmaceutical Design</i> , 2013 , 19, 5333-43 | 3.3 | 15 |
| 141 | NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?. <i>Current Medicinal Chemistry</i> , 2017 , 24, 4213-4228 | 4.3 | 14 |
| 140 | Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 504-15 | 8.9 | 14 |
| 139 | Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 718-728 | 8.9 | 14 |
| 138 | BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. <i>Lung Cancer</i> , 2016 , 95, 73-81 | 5.9 | 14 |
| 137 | Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. <i>Lung Cancer</i> , 2012 , 76, 457-64 | 5.9 | 14 |
| 136 | Factors driving the choice of the best second-line treatment of advanced NSCLC. <i>Reviews on Recent Clinical Trials</i> , 2011 , 6, 44-51 | 1.2 | 14 |

| | | | |
|-----|--|------|----|
| 135 | Management of unfit older patients with advanced NSCLC. <i>Cancer Treatment Reviews</i> , 2009 , 35, 517-21 | 14.4 | 14 |
| 134 | The role of new targeted therapies in small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 51, 45-53 | 7 | 14 |
| 133 | Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 2696-2715 | 4.4 | 14 |
| 132 | ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e161-e163 | 8.9 | 13 |
| 131 | Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas. <i>Journal of Clinical Pathology</i> , 2016 , 69, 440-7 | 3.9 | 13 |
| 130 | Pemetrexed in advanced non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 311-7 | 4.1 | 13 |
| 129 | Chemotherapy of advanced non-small cell lung cancer in elderly patients. <i>Annals of Oncology</i> , 2006 , 17 Suppl 2, ii58-60 | 10.3 | 13 |
| 128 | Chemotherapy of advanced NSCLC in special patient population. <i>Annals of Oncology</i> , 2006 , 17 Suppl 5, v72-8 | 10.3 | 13 |
| 127 | Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 1993 , 29A, 1729-31 | 7.5 | 13 |
| 126 | Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?. <i>Journal of Thoracic Disease</i> , 2014 , 6, 578-80 | 2.6 | 13 |
| 125 | Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors. <i>International Journal of Molecular Sciences</i> , 2019 , 20, | 6.3 | 12 |
| 124 | Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas. <i>International Journal of Surgical Pathology</i> , 2014 , 22, 401-7 | 1.2 | 12 |
| 123 | Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer. <i>Current Medicinal Chemistry</i> , 2009 , 16, 3919-30 | 4.3 | 12 |
| 122 | The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer. <i>Current Pharmaceutical Design</i> , 2012 , 18, 6155-68 | 3.3 | 12 |
| 121 | Paclitaxel plus bevacizumab for metastatic breast cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 1637; author reply 1637-8 | 59.2 | 12 |
| 120 | Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis. <i>Clinical Lung Cancer</i> , 2017 , 18, 23-33.e1 | 4.9 | 11 |
| 119 | High-grade neuroendocrine carcinoma. <i>Current Opinion in Pulmonary Medicine</i> , 2014 , 20, 332-9 | 3 | 11 |
| 118 | Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 747-58 | 5.4 | 10 |

| | | | |
|-----|---|-------|----|
| 117 | Emerging drugs targeting PD-1 and PD-L1: reality or hope?. <i>Expert Opinion on Emerging Drugs</i> , 2014 , 19, 557-69 | 3.7 | 10 |
| 116 | Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer. <i>Annals of Oncology</i> , 2015 , 26, 1035-1036 | 10.3 | 10 |
| 115 | CD90 expression in atypical meningiomas and meningioma metastasis. <i>American Journal of Clinical Pathology</i> , 2014 , 141, 841-9 | 1.9 | 10 |
| 114 | Is immunohistochemistry always required to diagnose lung cancer?. <i>Advances in Anatomic Pathology</i> , 2013 , 20, 327-33 | 5.1 | 10 |
| 113 | Erlotinib in non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 2579-92 | 4 | 10 |
| 112 | Overcoming Resistance to EGFR Inhibitors in NSCLC. <i>Reviews on Recent Clinical Trials</i> , 2016 , 11, 99-105 | 1.2 | 10 |
| 111 | Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 151-163 | 4 | 9 |
| 110 | Emerging angiogenesis inhibitors for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2019 , 24, 71-81 | 3.7 | 9 |
| 109 | Primary Sarcomatoid Carcinoma of the Lung: Radiometabolic ((18)F-FDG PET/CT) Findings and Correlation with Clinico-Pathological and Survival Results. <i>Lung</i> , 2016 , 194, 653-7 | 2.9 | 9 |
| 108 | Optimal drugs for second-line treatment of patients with small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 969-76 | 4 | 9 |
| 107 | "Dry" pleural mesothelioma successfully diagnosed on endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA). <i>Internal Medicine</i> , 2014 , 53, 467-9 | 1.1 | 9 |
| 106 | LUX-Lung: determining the best EGFR inhibitor in NSCLC?. <i>Lancet Oncology</i> , 2015 , 16, 118-9 | 21.7 | 9 |
| 105 | Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. <i>Targeted Oncology</i> , 2011 , 6, 171-80 | 5 | 9 |
| 104 | New avenues for second-line treatment of metastatic non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 115-24 | 3.5 | 9 |
| 103 | Challenges treating older non-small cell lung cancer patients. <i>Annals of Oncology</i> , 2008 , 19 Suppl 7, vii109-113 | 10.13 | 9 |
| 102 | Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature. <i>Oncology</i> , 2003 , 64, 353-60 | 3.6 | 9 |
| 101 | The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer. <i>Reviews on Recent Clinical Trials</i> , 2008 , 3, 217-27 | 1.2 | 9 |
| 100 | Bronchial fibroepithelial polyp: a clinico-radiologic, bronchoscopic, histopathological and in-situ hybridisation study of 15 cases of a poorly recognised lesion. <i>Clinical Respiratory Journal</i> , 2017 , 11, 43-48 ^{1.7} | 1.7 | 8 |

| | | | |
|----|---|------|---|
| 99 | Current challenges of lung cancer care in an aging population. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1419-29 | 3.5 | 8 |
| 98 | Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 363-372 | 5.9 | 8 |
| 97 | Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 96-8 | 8.9 | 8 |
| 96 | Carboplatin plus epirubicin plus VP-16, concurrent Oplit courseOradiotherapy and adjuvant surgery for limited small cell lung cancer. Gruppo Oncologico Centro-Sud-Isole (GOCSI). <i>Lung Cancer</i> , 1994 , 11, 83-91 | 5.9 | 8 |
| 95 | EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population. <i>Journal of Thoracic Disease</i> , 2012 , 4, 219-20 | 2.6 | 8 |
| 94 | Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2017 , 11, 171-180 | 3.8 | 7 |
| 93 | A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial. <i>Lung Cancer</i> , 2017 , 108, 15-21 | 5.9 | 7 |
| 92 | Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer. <i>Lancet Oncology, The</i> , 2017 , 18, 3-5 | 21.7 | 7 |
| 91 | New options for combination therapy for advanced non-squamous NSCLC. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 1095-1107 | 3.8 | 7 |
| 90 | The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?. <i>Clinical Lung Cancer</i> , 2010 , 11, 374-82 | 4.9 | 7 |
| 89 | Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. <i>Cancer</i> , 2004 , 101, 1733-44 | 6.4 | 7 |
| 88 | Biomarker analysis of the phase 3 TORCH trial for first line erlotinib chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017 , 8, 57528-57536 | 3.3 | 7 |
| 87 | Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , 2019 , 105, 3-14 | 1.7 | 6 |
| 86 | Cetuximab and non-small-cell lung cancer: end of the story?. <i>Lancet Oncology, The</i> , 2013 , 14, 1251-3 | 21.7 | 6 |
| 85 | An unusual case of cystic interstitial lung disease. <i>Lancet, The</i> , 2013 , 381, 1246 | 4.0 | 6 |
| 84 | The PI3k inhibitors: new hopes in the battle against advanced NSCLC. <i>Frontiers in Bioscience - Landmark</i> , 2014 , 19, 259-71 | 2.8 | 6 |
| 83 | Evaluation of ALK gene status in primary lung adenocarcinoma and matched metastases. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1146 | 8.9 | 6 |
| 82 | Bone metastases and non-small cell lung cancer: from bisphosphonates to targeted therapy. <i>Current Medicinal Chemistry</i> , 2012 , 19, 5524-35 | 4.3 | 6 |

| | | | |
|----|---|------|---|
| 81 | Surgical management of non-small cell lung cancer with mediastinal lymphadenopathy. <i>Clinical Oncology</i> , 2010 , 22, 325-33 | 2.8 | 6 |
| 80 | Irreversible EGFR inhibitors in the treatment of advanced NSCLC. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3894-900 | 3.3 | 6 |
| 79 | New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer. <i>Current Pharmaceutical Design</i> , 2015 , 21, 4763-72 | 3.3 | 6 |
| 78 | The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2016 , 4, 215 | 3.2 | 6 |
| 77 | Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirus-6B reactivation. <i>British Journal of Haematology</i> , 2016 , 172, 561-72 | 4.5 | 5 |
| 76 | 2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapy. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S248-57 | 7.5 | 5 |
| 75 | Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question. <i>Cancer Treatment Reviews</i> , 2010 , 36 Suppl 3, S30-3 | 14.4 | 5 |
| 74 | Non-small-cell lung carcinoma vaccines in clinical trials. <i>Expert Review of Vaccines</i> , 2011 , 10, 887-97 | 5.2 | 5 |
| 73 | Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2600; author reply 2601-2 | 7.2 | 5 |
| 72 | Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter?. <i>Annals of Oncology</i> , 2008 , 19, 402-3 | 10.3 | 5 |
| 71 | Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1444-5; author reply 1446 | 2.2 | 5 |
| 70 | A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. <i>Oncology</i> , 2002 , 62, 209-15 | 3.6 | 5 |
| 69 | Treatment of locally advanced non-small cell lung cancer in the elderly. <i>Current Opinion in Oncology</i> , 2005 , 17, 130-4 | 4.2 | 5 |
| 68 | PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019 , 11, 921-930 | 3.8 | 5 |
| 67 | Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2015 , 88, 319-24 | 5.9 | 4 |
| 66 | Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 233-42 | 8.9 | 4 |
| 65 | The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. <i>Reviews on Recent Clinical Trials</i> , 2013 , 8, 23-8 | 1.2 | 4 |
| 64 | Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2011 , 12, 70-3 | 4.9 | 4 |

| | | | |
|----|---|------|---|
| 63 | Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT). <i>Lung Cancer</i> , 2010 , 67, 339-42 | 5.9 | 4 |
| 62 | The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009 , 1, 5-13 | 5.4 | 4 |
| 61 | New insights in drug development for the non-small cell lung cancer therapy. <i>Frontiers in Bioscience - Landmark</i> , 2008 , 13, 5108-19 | 2.8 | 4 |
| 60 | Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly?. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4066-7; author reply 4067-8 | 2.2 | 4 |
| 59 | Synchronous Bilateral Retinal Metastases from Lung Adenocarcinoma. <i>Tumori</i> , 2005 , 91, 287-289 | 1.7 | 4 |
| 58 | Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1996 , 37, 613-5 | 3.5 | 4 |
| 57 | Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. <i>Lung Cancer</i> , 2020 , 140, 71-79 | 5.9 | 4 |
| 56 | A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3264-3275 | 4.4 | 4 |
| 55 | Hemoptysis and Progressive Dyspnea in a 67-Year-Old Woman with History of Renal Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, e12-3 | 10.2 | 3 |
| 54 | Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 1281-1288 | 5.5 | 3 |
| 53 | Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy. <i>Current Drug Targets</i> , 2010 , 11, 865-8784 | 3 | 3 |
| 52 | Thalidomide in small-cell lung cancer: is it a tombstone?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 160; author reply 160 | 2.2 | 3 |
| 51 | Italian clinical research in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2005 , 16 Suppl 4, iv110-115 | 10.3 | 3 |
| 50 | Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?. <i>Seminars in Oncology</i> , 2018 , 45, 176-180 | 5.5 | 3 |
| 49 | Fishing for ALK with immunohistochemistry may predict response to crizotinib. <i>Tumori</i> , 2013 , 99, e229-32.7 | | 3 |
| 48 | The safety of second-line treatment options for non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 471-479 | 4.1 | 2 |
| 47 | Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2015 , 9, 245-54 | 3.8 | 2 |
| 46 | Chickenpox in unexplained pulmonary necrotizing granulomas. <i>Chest</i> , 2014 , 145, 433-4 | 5.3 | 2 |

| | | | |
|----|---|------|---|
| 45 | Everolimus effectively blocks pulmonary metastases from meningioma. <i>Neuro-Oncology</i> , 2015 , 17, 1301-2 | | 2 |
| 44 | New angiogenic agents and non-small cell lung cancer: current results and future development. <i>Targeted Oncology</i> , 2007 , 2, 211-223 | 5 | 2 |
| 43 | Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996 , 19, 589-91 | 2.7 | 2 |
| 42 | Malignant Pigmented Mass "Sequestered" in the Lung: A Unique Case Report. <i>Lung</i> , 2016 , 194, 699-701 | 2.9 | 2 |
| 41 | Chickenpox-Related Multiple Pulmonary Granulomas: A Poorly Recognized Entity. <i>Lung</i> , 2016 , 194, 329-309 | | 2 |
| 40 | Rapid evaluation from used H&E, IHC and FISH diagnostic slides with the Idylla platform. <i>Journal of Clinical Pathology</i> , 2021 , | 3.9 | 2 |
| 39 | Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer. <i>Oncology</i> , 2010 , 24, 1216-23 | 1.8 | 2 |
| 38 | Selection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase Inhibitors. <i>Radiology and Oncology</i> , 2017 , 51, 241-251 | 3.8 | 1 |
| 37 | Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , 2019 , 133, 62-68 | 5.9 | 1 |
| 36 | MET DNA Alterations in NSCLC-Letter. <i>Clinical Cancer Research</i> , 2016 , 22, 3697-8 | 12.9 | 1 |
| 35 | Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology. <i>Tumori</i> , 2016 , 102, 108-13 | 1.7 | 1 |
| 34 | Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. <i>Lung Cancer</i> , 2011 , 74, 544-8 | 5.9 | 1 |
| 33 | Switch maintenance versus second-line treatment in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1298 | 8.9 | 1 |
| 32 | Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients. <i>Targeted Oncology</i> , 2006 , 1, 13-22 | 5 | 1 |
| 31 | Management of non-small cell lung cancer in elderly patients. <i>European Journal of Cancer, Supplement</i> , 2004 , 2, 15-25 | 1.6 | 1 |
| 30 | Chemotherapy of Advanced Nsclc in the Elderly. <i>Tumori</i> , 2002 , 88, S143-S144 | 1.7 | 1 |
| 29 | NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows. <i>Expert Opinion on Therapeutic Targets</i> , 2021 , 1-11 | 6.4 | 1 |
| 28 | Neuroendocrine-Related Circulating Transcripts in Small-Cell Lung Cancers: Detection Methods and Future Perspectives. <i>Cancers</i> , 2021 , 13, | 6.6 | 1 |

| | | | |
|----|--|-----|---|
| 27 | When Acute Respiratory Distress Syndrome is not ARDS. <i>Lung</i> , 2016 , 194, 865-6 | 2.9 | 1 |
| 26 | Drug Interactions and Polypharmacy 2013 , 89-106 | | 1 |
| 25 | Chondromyxoid fibroma of the nasal cavity in a pediatric patient: Case report and literature review. <i>International Journal of Pediatric Otorhinolaryngology Extra</i> , 2013 , 8, 39-43 | | 0 |
| 24 | A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors.. <i>Translational Lung Cancer Research</i> , 2021 , 10, 4511-4525 | 4.4 | 0 |
| 23 | A pulmonary tumor-like mass resolving with antibiotics. <i>Clinical Respiratory Journal</i> , 2016 , 10, 811-813 | 1.7 | |
| 22 | Agents in the preclinical development stage for non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1361-6 | 3.5 | |
| 21 | Approved and emerging treatments of malignant pleural mesothelioma in elderly patients. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 1179-1188 | 3.8 | |
| 20 | Second line in NSCLC: new opportunities?. <i>Lung Cancer Management</i> , 2015 , 4, 1-4 | 2.6 | |
| 19 | Potential role of histone deacetylase inhibitors in the treatment of advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2014 , 3, 255-261 | 2.6 | |
| 18 | Small-cell lung cancer: state-of-the-art treatment. <i>Lung Cancer Management</i> , 2012 , 1, 47-54 | 2.6 | |
| 17 | Disparities in subgroup populations enrolled in lung cancer trials. <i>Expert Review of Respiratory Medicine</i> , 2012 , 6, 163-72 | 3.8 | |
| 16 | Clinical results with EGFR inhibitors in NSCLC and their use in the treatment of metastatic disease 2012 , 34-43 | | |
| 15 | A clear case of chronic aspiration of starch (potato). <i>Clinical Respiratory Journal</i> , 2013 , 7, 416-8 | 1.7 | |
| 14 | The PARAMOUNT trial: implications for maintenance therapy in lung cancer patients. <i>Lung Cancer Management</i> , 2013 , 2, 243-246 | 2.6 | |
| 13 | Is there a role for maintenance therapy in advanced non-small-cell lung cancer?. <i>Clinical Practice (London, England)</i> , 2012 , 9, 77-86 | 3 | |
| 12 | Non-small-cell lung cancer: targeted therapies. <i>Therapy: Open Access in Clinical Medicine</i> , 2009 , 6, 95-98 | | |
| 11 | Overview of clinical trials for lung cancer in the elderly. <i>Aging Health</i> , 2008 , 4, 629-642 | | |
| 10 | Erlotinib in a previously treated advanced non-small cell lung cancer elderly patient: a clinical case. <i>Targeted Oncology</i> , 2006 , 1, 56-58 | 5 | |

- 9 Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. *Current Cancer Therapy Reviews*, **2007**, 3, 226-235 0.4
- 8 Three course chemotherapy is as effective as six courses for non-small-cell lung cancer. *Evidence-based Oncology*, **2001**, 2, 163-165
- 7 First-line therapy of advanced non-small cell lung cancer not harboring an activating EGFR mutation **2012**, 59-74
- 6 EGFR inhibitors and their use in the treatment of metastatic disease **2012**, 18-32
- 5 First-Line Treatment and the New Paradigm of Histology-Based Treatment **2013**, 187-200
- 4 Treatment of Frail Patients and Octogenarians with Advanced NSCLC **2013**, 201-212
- 3 Impact of the Physiological Effects of Aging on the Pharmacokinetics and Pharmacodynamics of Systemic Lung Cancer Treatment **2013**, 65-87
- 2 Are Second- and Third-Line Treatments in the Elderly Feasible? **2013**, 213-220
- 1 Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report.. *Translational Lung Cancer Research*, **2022**, 11, 686-696 4.4